News for Esperion Therapeutics, Inc. (0IIM.L)

BOSTON, July 15, 2025 (GLOBE NEWSWIRE) -- Aegle Therapeutics, a clinical-stage dermatology-focused biopharmaceutical company developing novel therapies for those living with rare and severe skin diseases, today announced the appointment of Scott Braunstein, M.D., as Chairman of the Board. The company’s lead product candidate AGLE-102, a composite of mesenchymal stem cell derived extracellular vesicles (MSC-EVs), is currently being evaluated in a Phase 1/2a trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare pediatric skin blistering disorder.

Brings More Than Twenty Years of Biopharmaceutical Leadership Experience

**media[661861]**

On June 17, 2025, HC Wainwright & Co. released an analyst report regarding Esperion Therapeutics (ESPR). The report reaffirms a "Buy" rating for the company, ma

Esperion's stock rebounds with strong prescription growth and Medicare resolution. Pipeline developments could be transformative. See more ESPR here.

ANN ARBOR, Mich., June 02, 2025 (GLOBE NEWSWIRE) -- Esperion ( ESPR) today announced that it has entered into a settlement agreement with Hetero USA, Inc. and

Esperion Therapeutics, Inc. (ESPR) has successfully resolved a patent dispute with Hetero USA, Inc. and its related entities, including Hetero Labs Limited, Het

Esperion (ESPR) has finalized a settlement with Micro Labs USA, Inc. and its affiliate, resolving a patent lawsuit initiated by Esperion. This legal action was

ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion ( ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc.

ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion ( ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3r

**media[620327]**

Esperion (ESPR) has awarded 49,300 restricted stock units (RSUs) to 15 new employees under its 2017 Inducement Equity Incentive Plan. The RSUs will vest

**media[619718]**

**media[618706]**

On May 7, 2025, Needham analyst Serge Belanger released an updated assessment on Esperion Therapeutics (ESPR), maintaining the stock's

Total Revenue: $65 million for Q1 2025, a 63% year-over-year increase after adjusting for a onetime milestone in Q1 2024.US Net Product Revenue: $34.9 million,

May 06, 2025 / 12:00PM GMTOperator Ladies and gentlemen, thank you for standing by, and welcome. (Operator Instructions) Please be advised that today's conferen

VANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. ( CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CC

Esperion Therapeutics (ESPR) to present at the Citizens Life Sciences Conference on May 8, 2025. The company's FDA-approved non-statin medicines address